RESUMEN
BACKGROUND & AIMS: The development of COVID-19 vaccines has progressed with encouraging safety and efficacy data. Concerns have been raised about SARS-CoV-2 vaccine responses in the large population of patients with non-alcoholic fatty liver disease (NAFLD). The study aimed to explore the safety and immunogenicity of COVID-19 vaccination in NAFLD. METHODS: This multicenter study included patients with NAFLD without a history of SARS-CoV-2 infection. All patients were vaccinated with 2 doses of inactivated vaccine against SARS-CoV-2. The primary safety outcome was the incidence of adverse reactions within 7 days after each injection and overall incidence of adverse reactions within 28 days, and the primary immunogenicity outcome was neutralizing antibody response at least 14 days after the whole-course vaccination. RESULTS: A total of 381 patients with pre-existing NAFLD were included from 11 designated centers in China. The median age was 39.0 years (IQR 33.0-48.0 years) and 179 (47.0%) were male. The median BMI was 26.1 kg/m2 (IQR 23.8-28.1 kg/m2). The number of adverse reactions within 7 days after each injection and adverse reactions within 28 days totaled 95 (24.9%) and 112 (29.4%), respectively. The most common adverse reactions were injection site pain in 70 (18.4%), followed by muscle pain in 21 (5.5%), and headache in 20 (5.2%). All adverse reactions were mild and self-limiting, and no grade 3 adverse reactions were recorded. Notably, neutralizing antibodies against SARS-CoV-2 were detected in 364 (95.5%) patients with NAFLD. The median neutralizing antibody titer was 32 (IQR 8-64), and the neutralizing antibody titers were maintained. CONCLUSIONS: The inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD. LAY SUMMARY: The development of vaccines against coronavirus disease 2019 (COVID-19) has progressed rapidly, with encouraging safety and efficacy data. This study now shows that the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in the large population of patients with non-alcoholic fatty liver disease.
Asunto(s)
Anticuerpos Neutralizantes/sangre , Anticuerpos Antivirales/sangre , COVID-19 , Inmunogenicidad Vacunal/inmunología , Enfermedad del Hígado Graso no Alcohólico , Vacunación , Vacunas de Productos Inactivados , Adulto , COVID-19/epidemiología , COVID-19/prevención & control , Vacunas contra la COVID-19/administración & dosificación , Vacunas contra la COVID-19/efectos adversos , China/epidemiología , Femenino , Humanos , Masculino , Enfermedad del Hígado Graso no Alcohólico/diagnóstico , Enfermedad del Hígado Graso no Alcohólico/epidemiología , Evaluación de Resultado en la Atención de Salud , SARS-CoV-2/inmunología , Vacunación/efectos adversos , Vacunación/métodos , Vacunación/estadística & datos numéricos , Vacunas de Productos Inactivados/administración & dosificación , Vacunas de Productos Inactivados/efectos adversosRESUMEN
Waste crude oil emulsion was inevitably produced in the petroleum industrial process, causing harmful impact on the ecological and social environment. In this study, rhamnolipid was for the first time investigated for demulsification of waste crude oil. As found in this paper, rhamnolipid treatment could obtain over 90% of dewatering efficiency on refractory waste crude oil and such efficient demulsification was confirmed on model emulsions. As further demonstrated on the pilot scale (100 L), rhamnolipid treatment could recover over 98% of crude oil from the wastes. The recovered oil contained less than 0.3% of water and thus can directly re-enter into refinery process while the aqueous phase can be disposed into dischargeable water due to largely reduced soluble COD after subjected to 5 days of active sludge treatment. It seems that rhamnolipids as biodemulsifiers were of great prospects in the industrial demulsification of waste crude oil.